OBJECTIVE: To analyze the ABO serological and molecular characteristics of a Chinese pedigree carrying an ABO*cisAB.01 allele for the blood subgroup. METHODS: A proband undergoing blood preparation for a surgery due to an open rupture of the extensor hallucis longus tendon in the left thumb on September 5, 2024 at Weihai Central Hospital and his family members were selected as study subjects. ABO serological type of six individuals from three generations was determined by serological methods. PCR was carried out to amplify exons 6 and 7 of the ABO gene, and the amplified products were directly sequenced. Samples of the proband and his mother, son, and daughter were subjected to clone sequencing analysis. This study was approved by the Medical Ethics Committee of Weihai Central Hospital (Ethics No.: LL-2024-269-01). RESULTS: Serological testing showed that the proband and his mother were of the AB subtype, whilst his daughter was A subtype B, his father was of O, his wife was AB, and his son was A. Direct sequencing showed that the proband's genotype was ABO*cisAB.01/O.01.02, and his mother, son, and daughter had all carried an ABO*cisAB.01 allele. There were significant differences in allelic competition when the A, B and O genes were co-dominant with the cisAB.01 allele, respectively. CONCLUSION There is allelic competition between the cisAB.01 allele and different ABO alleles. Blood type serological tests combined with molecular methods and family investigations can help ascertain and interpret the ABO blood type phenotypes.
Humans ; ABO Blood-Group System/genetics* ; Male ; Female ; Phenotype ; Pedigree ; Alleles ; Genotype ; Adult ; Asian People/genetics*

ObjectiveTo explore the effects of ziprasidone and risperidone on cognitive inhibition function through visual pathway of patients with paranoid schizophrenia.MethodsIn the open-label,flexible-dosage trial,124 patients with paranoid schizophrenia were randomly divided into ziprasidone group (120-160 mg/d)and risperidone group(4-8 mg/d) for treatment of 8 weeks.They were assessed with computerized Color Word Test (CWT) and Continuous Performance Test(CPT) through visual pathway for cognitive inhibition function,Positive and Negative Syndrome Scale for efficacy on baseline and 8th weekend.ResultsAfter treatment with ziprasidone,the error number (3.12 ± 5.23 ),the time per correct answer( ( 1.92 ± 1.38 ) s) of CWT,as well as the doubledigit mistaken number (2.31 ± 3.76)and the three-figure mistaken number( 3.15 ±2.80) of CPT reduced more than those before medication ( (4.60 ± 6.80),( 2.74 ± 1.52 ) s,(3.85 ± 3.62 ),(4.42 ± 3.53 ) ) (P ＜ 0.05 ).In risperidone.group,the double-digit mistake number of CPT(3.39 ± 3.59) after pharmacotherapy reduced more than that before pharmacotherapy(4.23 ± 3.88) (P＜ 0.05).After treatment the time per correct answer of CWT and the mistaken numbers of CPT in ziprasidone group were less than those in risperidone group(P＜ 0.05 ),meanwhile,the scores of PANSS in two groups were significantly lower than those before treatment (P ＜ 0.01 ).ConclusionIt is effective for ziprasidone and risperidone to improve the function of cognitive inhibition on patients with paranoid schizophrenia,but there is more dramatic for ziprasidone in short-term treatment.